ArticleJIMD reports2018

Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1.

Nathalie Guffon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.